ArticleBiomarker research2026
EGF as a non-invasive biomarker of endometriosis: a case control study.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is a chronic inflammatory condition that affects an estimated 1 in 10 women but is often mis- and underdiagnosed due to its non-specific symptoms and the lack of a non-invasive diagnostic test. This study aimed to identify and validate a potential non-invasive biomarker for endometriosis. This study applied quantitative proteomics discovery approaches to identify and validate non-invasive biomarkers of endometriosis with a long-term goal of leveraging them for purposes of diagnosis and therapeutic monitoring. Isobaric tags for relative and absolute quantification (iTRAQ) combined with mass spectrometry were used to identify and quantitate proteins and peptides in urine samples from participants with surgically-confirmed endometriosis (n = 73) and 1:1 age-matched participants never diagnosed with endometriosis (n = 73). Among those aged 25-47 at urine collection, Epidermal Growth Factor (EGF) (validated using monospecific enzyme-linked immunosorbent assays (ELISA)) was present at significantly lower levels in the urine of participants with surgically-confirmed endometriosis compared to controls (P = 0.02) and had an excellent negative predictive value (NPV) of 94.3% with a cutoff of > 800 pg/ug as determined by Bayes' formula. Urinary EGF levels were also significantly lower in the urine of participants aged 25-47 with endometriosis who experience acyclic pelvic pain compared to samples from age-matched controls who did not report acyclic pelvic pain (P = 0.007) such that the presence of acyclic pelvic pain increased the NPV of EGF to 96.8% as determined by Bayes' formula. These data demonstrate that urinary EGF has potential as a novel, non-invasive, accurate and objective biomarker for endometriosis diagnosis and prognosis of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.